| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/50 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CELF; CRP3; C/EBP-delta; NF-IL6-beta |
| WB Predicted band size | 28 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human CEBPD |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于CEBPD抗体的参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**: "CEBPD antibody application in cancer cell signaling studies"
**作者**: Li et al.
**摘要**: 研究利用特异性CEBPD抗体检测肿瘤细胞中CEBPD的表达，发现其在乳腺癌细胞中显著上调，并通过调控EMT通路促进转移。
2. **文献名称**: "Role of CEBPD in macrophage polarization: Insights from antibody-based assays"
**作者**: Zhang & Wang
**摘要**: 通过免疫印迹和免疫荧光(使用CEBPD抗体)，揭示CEBPD在巨噬细胞M1/M2极化中的调控作用，关联炎症性疾病进展。
3. **文献名称**: "Development of a high-affinity monoclonal antibody for CEBPD and its diagnostic potential"
**作者**: Kim et al.
**摘要**: 报道一种新型CEBPD单克隆抗体的开发，验证其在肝癌组织中的诊断特异性，并证明CEBPD高表达与患者预后不良相关。
(注：以上文献为示例，实际引用需查询真实数据库如PubMed。)
The CEBPD (CCAAT/Enhancer-Binding Protein Delta) antibody is a crucial tool for studying the CEBPD protein, a member of the C/EBP family of transcription factors. CEBPD regulates genes involved in inflammation, cell differentiation, proliferation, and apoptosis. It plays roles in immune responses, metabolism, and cancer progression by binding to DNA as a homodimer or heterodimer with other C/EBP proteins. Dysregulation of CEBPD is linked to tumorigenesis, metastasis, and chemoresistance in cancers, as well as neurodegenerative and metabolic disorders.
CEBPD antibodies are widely used in techniques like Western blotting, immunohistochemistry, and chromatin immunoprecipitation (ChIP) to detect protein expression, localization, and DNA-binding activity. These antibodies help researchers investigate CEBPD's dynamic expression under stress, hormonal changes, or pathological conditions. Validated antibodies are essential for ensuring specificity, often confirmed via knockout controls or siRNA knockdown. Commercial CEBPD antibodies are typically developed in rabbits or mice using immunogenic peptide fragments. Their applications span cancer biology, immunology, and metabolic disease research, providing insights into molecular mechanisms and potential therapeutic targets. Proper validation remains critical due to potential cross-reactivity with homologous C/EBP family members.
×
